Replies to post #205058 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Not much. NTRP is way behind in their research. They've promised MS and not delivered.

XenaLives, if NTRP has a highly successful trial result, what will that mean for AVXL?

Anavex has trials for three different CNS diseases ongoing and a partnership for Schizophrenia study with Big Pharma in the mix.

NTRP has to first catch up on the depth of the data (severely impaired AD for a few weeks won't cut it). Then they have to prove they can make an affordable product. This will take several years and by then Anavex will be established SOC care they will have to PROVE their compound is better.

I don't remember seeing any gut microbiome data from NTRP. Regeneration of neurons could be the equivalent of jumping a dead battery.. It may get you home, but don't expect to get to work on time the next morning.



All IMO.. of course... LOL!

[seventhwave]

NTRP's compound is highly toxic and its use can only be justified on the very severe Alzheimers cases. AVXL is testing on mild Alz cases on which the benefit vs. toxicity tradeoff from NTRP's compound cannot even begin to be justified. Therefore, even of their current trial is successful, they won't even try. Secondly, NTRP's trial is very short (prob. because of toxicity) and therefore demonstration of a reversal in severe consition is key. In contrast, demonstration a long duration of benefit is a key requirement in mild & moderste cases.